[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369492-105":59,"doc-detail-369492-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","whole-genome-sequencing-improves-tissue-of-origin-diagnosis-and-treatment-options-for-cancer-of-unknown-primary","Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary","","Whole genome and transcriptome sequencing (WGTS) for 72 patients with cancer of unknown primary (CUP) demonstrates diagnostic and therapeutic advantages over targeted panel testing. Across 71 paired cases, WGTS outperforms panel testing by detecting all reportable DNA features plus additional diagnostically or therapeutically relevant mutations in 76% of cases. A WGTS-informed CUP prediction algorithm (CUPPA), trained on known cancer types, supports tissue-of-origin (TOO) determination in 71% of cases that remain undiagnosed by clinicopathology review. WGTS also informs treatments for 79% of patients versus 59% for panel testing. When high tumour fraction cell-free DNA is available, plasma cfDNA enables higher-likelihood CUPPA predictions in 41% of cases, using routine pathology samples.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/whole-genome-sequencing-improves-tissue-of-origin-diagnosis-and-treatment-options-for-cancer-of-unknown-primary/369492/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/whole-genome-sequencing-improves-tissue-of-origin-diagnosis-and-treatment-options-for-cancer-of-unknown-primary/369492.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What approach does the article use to study CUP patients?","Question",{"text":112,"@type":113},"It applies whole genome and transcriptome sequencing (WGTS) to CUP tumours from 72 patients, with comprehensive comparison to cancer panel testing and, in selected cases, WGS of plasma cell-free DNA.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does WGTS compare with panel testing for diagnosis?",{"text":117,"@type":113},"WGTS shows diagnostic superiority over panel testing, detecting all reportable DNA features from panels and additional mutations of diagnostic or therapeutic relevance in 76% of paired cases.",{"name":119,"@type":110,"acceptedAnswer":120},"How is the tissue-of-origin prediction performed?",{"text":121,"@type":113},"A CUP prediction algorithm (CUPPA) trained on WGTS data of known cancer types is used to inform tissue-of-origin predictions, improving TOO determination in cases otherwise undiagnosed by clinicopathology review.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369492,1790480379,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article [https://doi.org/10.1038/s41467-025-59661-x](https://doi.org/10.1038/s41467-025-59661-x)  \nWhole genome sequencing improves tissueof-origin diagnosis andtreatment optionsfor cancer of unknown primary  \nReceived: 8 August 2024  \n\n| Accepted: 23 April 2025 |\n| --- |\n| |\n| Check for updates |\n\nRichard J. Rebello 1,2,20, Atara Posner 1,2,20, Ruining Dong 1,2,  \nOwen W. J. Prall3, Tharani Sivakumaran4,5, Camilla B. Mitchell 1,2, Aidan Flynn1,2, Alex Caneborg1,2, Catherine Mitchell 3,5, Sehrish Kanwal 1,2, Clare Fedele1,2, Samantha Webb6, Krista Fisher6, Hui-Li Wong 4,5, Shiva Balachander 3, Wenying Zhu1,2, Shannon Nicolson 1,2, Voula Dimitriadis2, Nicholas Wilcken7,  \nAnna DeFazio 7,8,9, Bo Gao10, Madhu Singh11, Ian M. Collins 12, Christopher Steer 13, Mark Warren14, Narayan Karanth15, Huiling Xu3, Andrew Fellowes 3, Rodney J. Hicks 16, Kym Pham Stewart2, Charles Shale 17, Peter Priestley17, Sarah-Jane Dawson 2,5,6, Joseph H. A. Vissers 1,2, Stephen B. Fox 3,5, Penelope Schoﬁeld5,18,19, David Bowtell5,6, Oliver Hofmann1,2, Sean M. Grimmond 2,  \nLinda Mileshkin 4,5,6,21 & Richard W. Tothill 1,2,5,21   \nGenomics can inform both tissue-of-origin (TOO) and precision treatments for patients with cancer of unknown primary (CUP). Here, we use whole genome and transcriptome sequencing (WGTS) for 72 patients and show diagnostic superiority of WGTS over panel testing (386–523 genes) in 71 paired cases. WGTS detects all reportable DNA features found by panel as well as additional mutations of diagnostic or therapeutic relevance in 76% of cases. Curated WGTS features and a CUP prediction algorithm (CUPPA) trained on WGTS data of known cancer types informs TOO in 71% of cases otherwise undiagnosed by clinicopathology review. WGTS informs treatments for 79% of patients, compared to 59% by panel testing. Finally, WGS of cell-free DNA (cfDNA) from patients with a high cfDNA tumour fraction (>7%), enables high-likelihood CUPPA predictions in41%of cases. WGTSis therefore superior to panel testing, broadens treatment options, and is feasible using routine pathology samples and cfDNA.  \nCancers of unknown primary (CUP) are metastatic tumours for which atissue-of-origin (TOO) cannot be identiﬁed after standardised diagnostic investigations1. Although improvements in cancer diagnosticshave reduced the incidence of CUP in recent years, they still account for 1–3% of all new cancer diagnoses2. While a minority (~20%) of CUP patients have a favourable outcome corresponding to treatmentresponsive cancer types, most CUP patients have an unfavourable prognosis and empirical chemotherapy is generally ineffective1.  \nDNA sequencing can identify therapeutically actionable mutations in a third or more of CUP tumours3. The CUPISCO clinical trial showed that patients with unfavourable CUP who received molecular or immune-checkpoint targeting therapies based on tumour proﬁling data had improved progression-free survival following three cycles of induction chemotherapy when compared to platinum-chemotherapy treated controls4. Therefore, applying molecularly targeted treatmentsin CUP patients irrespective of the cancer’s origin is plausible, but  \nA full list of afﬁliations appears at the end of the paper. e-mail: [rtothill@unimelb.edu.au](rtothill@unimelb.edu.au)  \ndespite this, targeted treatments can still show variable efﬁcacy between cancer types5, while drug access is also often restricted to speciﬁc cancer types. Genomic tests that can resolve the primary cancer diagnosis and direct targeted treatments are therefore needed.  \nGenomic proﬁling has been used to predict a primary cancer TOO in CUP, with a number of studies utilising RNA expression6–8, DNA methylation9 or DNA mutations10–13. The application of DNA mutation data for TOO diagnosis is attractive as the same data also informs precision treatments. Some gene-speciﬁc mutations are enriched among certain cancer types, while the detection of mutational signatures, associated with ultraviolet light ","cbCaidTOV3WW4ypM","https://ap.wps.com/l/cbCaidTOV3WW4ypM","pdf",3182774,15,"English","# Results\n## Feasibility of clinical WGTS applied to a national CUP programme\n## Diagnostic superiority of WGTS over panel testing\n## TOO prediction using CUPPA\n## Treatment implications of WGTS vs panel testing\n## cfDNA-based WGS for high tumour fraction patients","[{\"question\":\"What approach does the article use to study CUP patients?\",\"answer\":\"It applies whole genome and transcriptome sequencing (WGTS) to CUP tumours from 72 patients, with comprehensive comparison to cancer panel testing and, in selected cases, WGS of plasma cell-free DNA.\"},{\"question\":\"How does WGTS compare with panel testing for diagnosis?\",\"answer\":\"WGTS shows diagnostic superiority over panel testing, detecting all reportable DNA features from panels and additional mutations of diagnostic or therapeutic relevance in 76% of paired cases.\"},{\"question\":\"How is the tissue-of-origin prediction performed?\",\"answer\":\"A CUP prediction algorithm (CUPPA) trained on WGTS data of known cancer types is used to inform tissue-of-origin predictions, improving TOO determination in cases otherwise undiagnosed by clinicopathology review.\"}]","Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary | PDF",1790183045,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbf3d18b9c4483f76a2ebd0d209d9e54.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3268b1adaf59a48de418363a97f369b5.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac649b8ac2b2a2c9796cab84d3dbf1df.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0959be7c7a08b05eb9834326189ee8bc.webp",980,1301]